Drug Profile
Uterine leiomyoma therapeutic - Eli Lilly and Company
Latest Information Update: 09 Feb 2011
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Uterine leiomyoma
Most Recent Events
- 24 Jan 2011 Discontinued - Phase-I for Uterine leiomyoma (unspecified route)
- 18 Oct 2010 Phase-I clinical trials in Uterine leiomyoma (unspecified route)